R-100 improves pulmonary function and systemic fluid balance in sheep with combined smoke-inhalation injury and *Pseudomonas aeruginosa* sepsis

Hiroshi Ito¹, Erik Malgerud¹, Sven Asmussen¹, Ernesto Lopez¹, Andrew L. Salzman² and Perenlei Enkhbaatar¹*

**Abstract**

**Background:** Septic shock is a major cause of death in intensive care units around the world. The aim of the study was to investigate whether the novel drug R-100 (a superoxide degradation catalyst and nitric oxide donor) improves pulmonary function in a sheep model of septic shock caused by *Pseudomonas aeruginosa* and smoke inhalation.

**Methods:** Eleven female sheep were prepared surgically and randomly assigned to a treatment group (n = 5) or a control group (n = 6) after inhalation of cooled cotton smoke and airway instillation of live *P. aeruginosa* (2.5 × 10¹¹ CFU) by bronchoscope under deep anesthesia and analgesia. The treatment group received an intravenous infusion of a total of 80 mg/kg of R-100 diluted in 500 mL of 5% dextrose. The control group was given 500 mL of 5% dextrose. All animals received intravenous lactated Ringer’s solution to maintain a hematocrit level at baseline ± 3%. Blood gas and hemodynamics were measured at baseline and then analyzed every 3 h during the 24-h study period. Results are expressed as mean ± SEM.

**Results:** The treated animals showed significant improvement in their pulmonary gas exchange (PaO₂/FiO₂ ratio at 24 h: 246 ± 29 vs. 90 ± 40 mmHg control, P < 0.05). Pulmonary arterial pressures were reduced in the treated group (24 h: 26 ± 1 vs. 30 ± 2 cm mmHg control, P < 0.05). The treated animals also had an improved total fluid balance after 24 h (190 ± 45/24 h mL vs. 595 ± 234/24 h mL control, P < 0.05).

**Conclusions:** Treatment with R-100 improves pulmonary gas exchange and blood oxygenation, and prevents a fluid imbalance in sheep subjected to smoke inhalation and *P. aeruginosa*.

**Keywords:** Sepsis, Redox, R-100, Smoke

**Background**

It is well known that patients with acute lung injury (ALI), who develop sepsis have a poor prognosis [1, 2]. In ALI-mediated sepsis, reactive oxygen species, such as superoxide are released as an effect of a massive inflammatory response [3, 4].

Oxidative stress is often implicated in the development of vascular dysfunction [5]. Under normal circumstances, superoxide is degraded by superoxide dismutase (SOD). However, during a forceful activation of neutrophils, as seen in sepsis, SOD becomes saturated and the level of superoxide becomes elevated [6–8]. An excess superoxide production can, aside from damaging endothelial cells, react nonenzymatically with nitric oxide (NO) to yield the more toxic product peroxynitrite (ONOO⁻), which causes vascular hyper-permeability and tissue damage [9–11].

Although excessive NO, especially iNOS-derived, is generally regarded as detrimental in sepsis pathophysiology, studies have instead shown that non-selective inhibition of NO production may cause pulmonary...
hypertension [12]. It is worth noting that increased pressure in pulmonary circulation during sepsis is associated with a reduced patient survival [13]. Numerous studies besides our own have shown that administration of inhaled NO may normalize increased pulmonary arterial pressure [14–16].

The aim of this study was to investigate the effects of simultaneous delivery of NO while limiting peroxynitrite formation by catalytically degrading superoxide. Promoting degradation of accumulated superoxide decreases vascular injury in sepsis by inhibiting production of peroxynitrite and improves pulmonary function by increasing the availability of NO in the pulmonary circulation. This pathway yields a potential therapeutic target in ALI and sepsis.

Currently, there are no studies investigating the combined effects of superoxide catalytic degradation and simultaneous augmentation of nitric oxide availability. R-100 (Radical Therapeutics, Inc., West Tisbury, MA) is a multifunctional redox active small molecule, comprising two distinct moieties: (1) an organic nitrate domain that donates nitric oxide, and (2) a nitroxide domain that serves as a redox degradation catalyst and removes superoxide anions and hydrogen peroxide. The fusion of both moieties into a single molecular entity allows for the donation of nitric oxide without concomitant generation of peroxynitrite via the diffusion-limited reaction of the donated NO with ambient superoxide anion. The administration of R-100 in septic sheep would hypothetically remove superoxide from the circulating blood, thus indirectly inhibiting production of peroxynitrite leading to an attenuation of vascular injury. Secondly, NO supplementation would be expected to decrease pulmonary circulatory pressures, decrease pulmonary shunt fraction and improve blood oxygenation. In the current study, the objective was to test these hypotheses using R-100 in a well-characterized ovine model of sepsis/septic shock.

**Methods**

Eleven adult female Merino sheep were surgically prepared and subjected to smoke inhalation injury followed by installation of *Pseudomonas aeruginosa* into the lungs. This study was approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch and conducted in compliance with the guidelines of the National Institutes of Health and the American Physiology Society for the care, handling, and use of laboratory animals. The studies were completed at the institution’s Translational Intensive Care Unit, which is a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.

**Surgical preparation**

The eleven sheep, weighing 35 ± 0.5 kg were surgically prepared for the experimental procedure. After induction of anesthesia with ketamine (Bioiche Pharma, Lake Forest, IL, 15–20 mg/kg) and under isoflurane anesthesia, a 16 G, 24 inch silastic catheter was inserted into the right femoral artery (Intracath, Becton–Dickinson, Sandy, UT, USA). A pulmonary arterial thermodilution catheter, model 131F7 was also positioned in the pulmonary artery through the right common jugular vein (Edwards Lifesciences LLC, Irvine, CA, USA). A silastic (0.062 inch ID) catheter was also inserted into the left atrium through a left thoracotomy in the fifth intercostal space (Dow Corning, Midland, MI, USA). Pre-emptive analgesia was provided with buprenorphine. Postoperative analgesia was maintained with continuous infusion of buprenorphine over 48 h and thereafter as needed.

**Experimental procedure**

After 5 days of recovery with free access to food and water, tracheostomy (Shiley 10 SCT, Tyco Healthcare, Pleasanton, CA) was performed under ketamine/isoﬂurane anesthesia and analgesia. Pneumonia and sepsis were induced by smoke inhalation and instillation of live *P. aeruginosa* into the lungs. Briefly, a modified bee smoker was filled with 40 g of smoke from cotton towel, and attached to the tracheostomy tube via a modified endotracheal tube containing an indwelling thermistor from a pulmonary arterial catheter to monitor the temperature of the smoke. Four sets of 12 breaths of cotton smoke (< 40 °C) were manually delivered. After each set, the arterial carboxyhemoglobin (COHb) level was measured with a 626 CO-Oximeter (Instrumentation Laboratory, Bedford, MA, USA) to ensure that all sheep received a similar level of injury. Immediately after the smoke injury, an amount of 2.5 × 10¹¹ Colony Forming Units (CFU) of live *P. aeruginosa* (PD-05144, 27317, ATCC) suspended in 30 mL of saline was instilled into the lungs through a bronchoscope. 20 mL were placed into the right lung (10 mL in the main bronchus of the middle lobe, and 10 mL in the main bronchus of the lower lobe) and 10 mL were instilled into the main bronchus of the left lower lobe, thus compensating for the extra lobe of the right lung. A urinary retention catheter (Foley 14 C.R., Bard Inc., Covington, GA) was placed into the urinary bladder via the urethra as well.

After this, a randomization occurred to either treatment with R-100 (n = 5) or placebo (n = 6). The experiment was conducted with two sheep being studied simultaneously side-by-side. Treatment was started 1 h post-injury. The treatment group received R-100 at a dose of 80 mg/kg in 500 mL of 5% dextrose. A bolus (30 min) of 10 mg/kg was followed by the remaining 70 mg/kg as
a continuous intravenous infusion over 24 h. The control group was treated with an equivalent amount of 5% dextrose. R-100 was kindly provided by Radikal Therapeutics, Inc. Dosage was based on previous studies results (Unpublished data). Mice were given 20, 40 or 80 mg/kg/day of intraperitoneal injection of R-100, which was started 1 h after LPS challenge. Although the severity of injury was attenuated with 20, 80 mg/kg had the most survival benefit (100% 7-day survival, while none of mice survived in non-treated control group). None of the animal groups received antibiotics before (at least 24 h) or during the experiment.

After the injury, the animals were awakened and maintained on mechanical ventilation (Servo Ventilator 300C, Siemens-Elema, Sweden) with a positive end-expiratory pressure (PEEP) of 5 cmH2O and a tidal volume of 12 mL/kg [17] during the 24 h experimental period. FiO2 was adjusted after 1 h and then every 3 h according to arterial blood gas analysis results to, as far as possible, maintain the arterial SaO2 > 90% and PaO2 at baseline (~ 100 mmHg). The respiratory rate was also adjusted to keep PaCO2 between 30 and 40 mmHg. Peak and plateau airway pressures were monitored throughout the experimental period. The animals received fluid resuscitation (Ringer's lactate, containing sodium 130 mmol/L, chloride 109 mmol/L, lactate 28 mmol/L, potassium 4 mmol/L, calcium 1.5 mmol/L), initially at a rate of 2 mL/kg/h, which was then adjusted to maintain hematocrit at baseline ± 3%. The maximum fluid infusion rate allowed was 15 mL/kg/h.

Plasma and urine samples were taken every 3 h during the 24-h experimental period. All sheep were euthanized at 24 h after the injury.

Measurements
Mean arterial pressure (MAP), left atrial pressure (LAP), central venous pressure (CVP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP) and heart rate (HR) were measured using pressure transducers (model P × 3 × 3; Baxter Edwards Critical Care Division, Irvine, CA) connected to a hemodynamic monitor (Intel-liVue MP50; Philips Medizin Systeme Boeblingen, Boeblingen, Germany). Cardiac output (CO) was determined by standard thermodilution method. Stroke volume index (SVI), systemic vascular resistance index (SVRI), pulmonary vascular resistance index (PVRI), left ventricle stroke work index (LVSWI), and right ventricle stroke volume index (RVSVI) were calculated by standard formula.

Arterial and mixed venous blood was drawn at baseline and then every 3 h for blood gas measurements by an analyzer (Premier 300, Instrumental Laboratory, Lexington, MA) and the results were corrected for body temperature.

Urinary output and fluid administration were measured at regular time intervals for calculation of fluid balance. Plasma protein concentration was measured by a refractometer.

The airway peak and plateau pressures were recorded from ventilator readouts. The bloodless lung wet-to-dry weight ratio was calculated according to the equation described by Pearce et al. [18]. Pulmonary shunt fraction (Qs/Qt), PaO2/FiO2 ratio, and systemic and pulmonary vascular resistance indexes were calculated according to standard formula.

Statistical analysis
The data were compared using analysis of variance (ANOVA) for repeated measures. Bonferroni post hoc tests were performed for comparisons between groups at each time point, and student’s t-tests were performed when appropriate. All values are expressed as mean ± standard error of the mean (SEM). The statistical analysis was performed using GraphPad Prism Software (GraphPad Software, La Jolla, CA, USA). P-values < 0.05 were considered significant.

Results
Baseline variables
There were no differences between the two study groups at baseline within the measured variables. Body weight was similar in both groups (35.4 ± 0.8 kg in the treatment group vs. 35.2 ± 0.9 kg in the control), and there were no differences in body surface area between the groups (0.91 ± 0.01 m2 in the treatment group vs. 0.91 ± 0.01 m2 in the control). The arterial COHb determined immediately after the smoke inhalation injury averaged 69.1 ± 2.0% in the control group and 64.4 ± 2.5% in the R-100 group; these levels were not significantly different from each other indicating a similar degree of injury. The core body temperatures similarly increased in both groups and remained comparable. Lactate levels after 3 h were 3.4 ± 1.1 mg/dL in the R-100 group and 2.9 ± 1.0 mg/dL in the control group, indicating tissue hypoxia in both groups. These values rose throughout the experiment and there were no differences between the groups.

Pulmonary gas exchange and global oxygen transport
The PaO2/FiO2 (P/F) ratio declined in both animal groups, however at 24 h the R-100 group had a
significantly higher P/F ratio than the control group (P < 0.05) (Fig. 1a). The pulmonary shunt fraction (Qs/Qt) increased in both groups implying that the fraction of the blood that was shunted past the lungs was higher as the experiment proceeded. The groups did not differ from each other with respect to mean Qs/Qt means (Fig. 1b).

Comparisons between the groups with respect to PaCO₂, SvO₂, PvO₂, and PvCO₂ did not show any significant differences. As mentioned, the FiO₂ was adjusted to keep SaO₂ above 90%. It was maintained above the targeted value throughout the study period; however, the SaO₂ in control sheep remained below 90% even with maximum increased FiO₂ (100%). At 24 h, SaO₂ was significantly higher in the R-100 sheep compared to control (Table 1).

The peak airway pressure increased in both groups vs. baseline. However, the R-100 group had a significantly lower peak airway pressure than the control group during the last 12 h of the experiment (P < 0.05). The pause airway pressure also increased in both groups, but was lower in the R-100 group (P < 0.05 at 24 h) (Fig. 2).

Cardiopulmonary hemodynamics
Comparisons between the groups with respect to heart rate, cardiac output, central venous pressure, pulmonary capillary wedge pressure left atrial pressure (increased in both groups vs. baseline) and mean arterial blood pressure and systemic vascular resistance index (decreased in both groups vs. baseline) showed no significant differences.

Pulmonary artery pressure increased throughout the experiment in both groups compared to baseline. However, at 24 h after injury, the R-100 sheep had a significantly lower pulmonary arterial pressure than the control sheep (P < 0.05) (Table 1).

Fluid balance and plasma protein content
Arterial hemoglobin and hematocrit levels were stable in both groups throughout the study period. Urine output declined in both groups between hours 12 and 18. The R-100 treated-animals appeared to excrete urine at a higher rate than the control group at 24 h, but the difference was not significant (Fig. 3a). The treated group required less fluid to maintain the hematocrit (Fig. 3b).

The body fluid accumulation tended to be higher in the control group throughout the study period. The vehicle-treated control sheep retained 595 ± 234 mL of fluid between 21 and 24 h vs. 190 ± 45 mL in R-100-treated sheep. A significant difference was noted at 24 h between the two groups (Fig. 4).

The post-mortem wet-to-dry weight ratio was slightly higher in the control group. However no significant differences were found between the groups (6.54 ± 0.53 in the control group vs. 6.03 ± 0.70 in the treatment group).

Histological analysis
Histological analysis did not show any significant differences between the two groups. However, the treatment group tended to having lower scores for all variables, including congestion, septal edema, alveolar edema, and alveolar polymorphonuclear neutrophils (Table 2).

Discussion
The main purpose of this large animal study was to investigate the combined effects of superoxide catalytic degradation and augmentation of nitric oxide by the novel agent R-100 using our well-characterized ovine model.
**Table 1** Hemodynamic data

|        | BL   | 3 h      | 6 h      | 9 h      | 12 h     | 15 h     | 18 h     | 21 h     | 24 h     |
|--------|------|----------|----------|----------|----------|----------|----------|----------|----------|
| **CO** |      |          |          |          |          |          |          |          |          |
| Control| 5.37 | 5.87     | 5.76     | 6.16     | 5.93     | 5.82     | 6.19     | 7.38     | 7.53     |
| R-100  | 5.58 | 6.07     | 6.16     | 6.63     | 6.99     | 6.93     | 6.81     | 6.62     | 6.63     |
| **MAP** |     |          |          |          |          |          |          |          |          |
| Control| 99   | 106      | 95       | 88       | 78       | 74       | 72       | 81       | 83       |
| R-100  | 95   | 99       | 103      | 98       | 84       | 76       | 73       | 85       | 84       |
| **HR** |      |          |          |          |          |          |          |          |          |
| Control| 85   | 97       | 114      | 116      | 112      | 115      | 116      | 123      | 122      |
| R-100  | 74   | 109      | 136      | 136      | 141      | 134      | 113      | 116      | 114      |
| **PAP** |     |          |          |          |          |          |          |          |          |
| Control| 195  | 23.3     | 23.7     | 25.3     | 26.0     | 26.2     | 27.8     | 29.6     | 30.2     |
| R-100  | 190  | 19.8     | 21.0     | 22.4     | 24.6     | 24.0     | 24.6     | 25.4     | 25.6     |
| **PCWP** |    |          |          |          |          |          |          |          |          |
| Control| 10.2 | 14.3     | 14.3     | 15.8     | 16.5     | 16.2     | 16.5     | 17.0     | 17.0     |
| R-100  | 10.2 | 13.2     | 13.6     | 14.4     | 14.2     | 13.6     | 14.4     | 15.0     | 14.8     |
| **CVP** |     |          |          |          |          |          |          |          |          |
| Control| 5.8  | 8.2      | 9.0      | 11.5     | 11.3     | 11.3     | 12.0     | 12.7     | 11.2     |
| R-100  | 5.8  | 7.8      | 7.8      | 9.2      | 9.2      | 12.0     | 13.0     | 11.0     | 10.8     |
| **LAP** |     |          |          |          |          |          |          |          |          |
| Control| 9.3  | 9.8      | 10.6     | 13.4     | 11.6     | 12.0     | 12.6     | 14.8     | 12.0     |
| R-100  | 8.2  | 9.0      | 9.2      | 11.2     | 12.2     | 12.4     | 13.6     | 12.8     | 13.0     |
| **SVI** |     |          |          |          |          |          |          |          |          |
| Control| 70.0 | 70.5     | 57.4     | 61.2     | 60.2     | 57.1     | 60.0     | 67.0     | 69.0     |
| R-100  | 84.0 | 62.8     | 50.5     | 54.3     | 55.3     | 57.9     | 67.1     | 63.0     | 64.5     |
| **SVRI** |    |          |          |          |          |          |          |          |          |
| Control| 1286 | 1259     | 1097     | 922      | 858      | 812      | 776      | 727      | 847      |
| R-100  | 1159 | 1093     | 1134     | 987      | 779      | 683      | 645      | 819      | 798      |
| **PVRI** |    |          |          |          |          |          |          |          |          |
| Control| 1280 | 1172     | 1209     | 1145     | 1177     | 1288     | 1609     | 1280     | 1530     |
| R-100  | 1158 | 805      | 872      | 881      | 1082     | 1094     | 1100     | 1172     | 1191     |
| **LVSWI** |   |          |          |          |          |          |          |          |          |
| Control| 85.0 | 90.6     | 62.4     | 59.4     | 51.0     | 43.7     | 45.3     | 57.0     | 60.0     |
| R-100  | 97.0 | 73.9     | 61.4     | 61.1     | 52.7     | 48.5     | 55.8     | 61.2     | 60.7     |
| **RVSWI** |   |          |          |          |          |          |          |          |          |
| Control| 12.9 | 14.8     | 11.3     | 11.3     | 12.2     | 11.7     | 12.3     | 15.0     | 17.0     |
| R-100  | 15.0 | 10.1     | 9.0      | 9.7      | 11.1     | 9.4      | 10.8     | 12.4     | 13.1     |
| **PaCO2** |   |          |          |          |          |          |          |          |          |
| Control| 37.8 | 25.6     | 27.3     | 26.4     | 27.8     | 26.7     | 29.3     | 26.6     | 36.2     |
| R-100  | 36.6 | 25.4     | 26.6     | 27.4     | 27.2     | 27.0     | 25.4     | 29.6     | 28.4     |
| **SaO2** |   |          |          |          |          |          |          |          |          |
| Control| 91.5 | 91.6     | 90.2     | 90.3     | 88.3     | 88.4     | 87.8     | 89.2     | 76.2     |
| R-100  | 91.4 | 93.8     | 90.0     | 90.2     | 896      | 885      | 903      | 917      | 91.9     |
| **PvO2** |   |          |          |          |          |          |          |          |          |
| Control| 47.3 | 47.0     | 47.0     | 47.8     | 46.3     | 53.2     | 52.3     | 54.8     | 46.8     |
| R-100  | 43.8 | 54.4     | 51.8     | 51.0     | 52.4     | 52.8     | 56.6     | 58.0     | 60.6     |
| **PvCO2** |   |          |          |          |          |          |          |          |          |
| Control| 44.5 | 32.7     | 32.5     | 30.8     | 30.7     | 28.7     | 32.5     | 32.4     | 41.2     |
| R-100  | 41.4 | 33.4     | 30.2     | 32.6     | 31.4     | 30.4     | 30.6     | 35.2     | 30.8     |
of severe sepsis. In the present study the treatment with R-100 limited increases in pulmonary arterial pressure, improved pulmonary gas exchange and reduced airway pressures in septic sheep.

Beneficial effects of the inhibition or reduction of oxidative stress in sepsis has been widely investigated [19–21]. Endothelial tissue injury caused by these reactive oxygen species is classically associated with fluid extravasation and accumulation in tissues, including the lungs [6]. There is a general consensus that the decline in pulmonary gas exchange is an effect of oxidative stress and tissue injury by metabolites, such as superoxide and peroxynitrite. In concordance, in this study we observed that catalytic degradation of superoxide by R-100 improved pulmonary gas exchange and that there was a tendency, although not significant, toward improvements
in tissue injury markers such as lung wet-to-dry weight ratio and histological analyses.

Nitric oxide synthase (NOS) represents a group of enzymes that catalyse NO synthesis. Depending on its location, three main subtypes are defined. Many investigators have described that selective inhibition of NOS isoforms i.e., iNOS or nNOS, shows a beneficial effect on the pathophysiology of ALI [16, 22]. In contrast, another study showed that non-selective inhibition of NOS may be detrimental in severe sepsis [24]. Studies have also reported an improvement in oxygenation in ARDS with NO-inhalation treatment [25]. Excessive NO, especially iNOS-derived NO, has been shown to blunt the pulmonary hypoxic vasoconstriction leading to increased shunt fraction (causing vasodilatation in less ventilated areas) that results in impaired arterial oxygenation. An alternative approach to reduce the shunt fraction is the NO supplementation, assuming that it would increase blood flow in well-ventilated areas, thus limiting the shunt fraction. NO supplementation may also benefit by reducing the pulmonary artery pressure, which is a detrimental complication of ALI leading to increased mortality. In this respect, the exogenous delivery of NO may benefit patients with ALI and sepsis. However, this approach might be detrimental in environments that are associated with severe oxidative stress, including our present model. Therefore, we combined the NO donor with the superoxide degradation catalyst, thus limiting the formation of more toxic product—peroxynitrite. In the present study, R-100 significantly reduced PAP and PCWP as expected although the therapy did not affect increased shunt fraction.

Another important finding in this study was that the fluid balance after 24 h was significantly improved by R-100. Previous studies have shown a massive systemic fluid retention as sepsis progresses [9, 23]. A positive fluid balance is an independent predictor of mortality in ICU patients with pulmonary edema [9, 24]. The improved fluid balance seen in these animals implies less fluid extravasation and accumulation. With respects to pulmonary edema, the histological data from this study also showed that, although not significant, R-100 appeared to decrease tissue injury and fluid accumulation in the alveoli.

The mechanistic aspects behind the beneficial effects of R-100 remain incompletely understood. As mentioned above, the inhibition of excessive NO is beneficial in ALI. However, our present study also suggests that exogenous delivery of NO in combination with a superoxide degradation catalyst may also represent an alternative approach for treatment of ALI. This interesting phenomenon deserves further studies to elucidate the precise mechanism(s) underlying the pleiotropic effects of NO in sepsis. There is also much that is unknown regarding the underlying mechanistic aspects of how R-100 reduces the fluid retention. Future follow-up studies are warranted to elucidate the precise mechanisms. The limitation of the current study is that we were unable to perform a dose-dependent evaluation of R-100. Additionally, we were not able to show data on the oxidative and nitrosative stress. Furthermore our studies were limited to only 24 h. The longer duration may have better illustrated prolonged treatment benefits (i.e., histological analyses and lung wet-to-dry weight ratio).

Nevertheless, treatment with R-100 in sheep subjected to smoke inhalation and P. aeruginosa sepsis ameliorates pulmonary hypertension, improves pulmonary gas exchange and reduces the systemic fluid retention.

**Conclusions**

R-100 in sheep subjected to smoke inhalation and P. aeruginosa sepsis ameliorates pulmonary hypertension, improves pulmonary gas exchange and reduces the systemic fluid retention. Further studies investigating the mechanistical aspects of R-100 are warranted.
Abbreviations

ALL: acute lung injury; ANOVA: analysis of variance; CFU: colony forming units; CO: cardiac output; COHb: carboxyhemoglobin; CVP: central venous pressure; FiO2: fraction inspired oxygen; HR: heart rate; ID: inside diameter; LAP: left atrial pressure; LVSWI: left ventricle stroke work index; MAP: mean arterial pressure; NO: nitric oxide; NOS: nitric oxide synthase; iNOS: inducible nitric oxide synthase; nNOSL: neuronal nitric oxide synthase; ONOO−: peroxynitrite; PaCO2: arterial partial carbon dioxide pressure; PaO2: arterial partial oxygen pressure; PvCO2: venous partial carbon dioxide saturation; PvO2: venous partial oxygen saturation; PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PEEP: positive end expiratory pressure; PMN: polymorphonuclear neutrophil; PVRI: pulmonary vascular resistance index; Qs/Qt: pulmonary shunt fraction; RVSM: right ventricle stroke work index; SaO2: arterial oxygen saturation; SvO2: venous oxygen saturation; SCL: single cannula tracheostomy; SEM: standard error of the mean; SOD: superoxide dismutase; SVI: stroke volume index; SVRI: systemic vascular resistance index.

Authors’ contributions

Hi, data collection, writing; EM, data collection, writing; SA, data collection; EL, data collection, analysis; AS, concept development, writing; PE, concept development, writing. All authors read and approved the final manuscript.

Author details

1 Department of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA. 2 Radikal Therapeutics, Inc., West Tisbury, MA, USA.

Acknowledgements

The authors thank the staff of the Translational Intensive Care Unit at the University of Texas Medical Branch for their valuable assistance in conducting these studies. We would like to acknowledge the contributions of the late Dr. Daniel Traber and Mrs. Lillian Traber.

Competing interests

Andrew Salzman is an employee of Radikal Therapeutics, inc. All other authors declare that they have no competing interests.

Availability of data and materials

Available through contact with the corresponding author.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch and conducted in compliance with the guidelines of the National Institutes of Health and the American Physiologic Society for the care, handling, and use of laboratory animals. The studies were completed at the institution’s Translational Intensive Care Unit, which is a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.

Funding

Funded through Grants SCH84050, SHC85500, NIH GM097480, and through Radikal Therapeutics, inc. The funding agencies had no role in the study design or execution.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 August 2016    Accepted: 12 December 2017    Published online: 28 December 2017

References

1. Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest. 1999;116:74–82.
2. Brown SDARDS. History, definitions, and physiology. Respir Care Clin N Am. 1998;4:567–82.
3. Macartthur H, Westfall T, Riley D, et al. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Poc Natl Acad Sci USA. 2000;97:9753–8.
4. Macartthur H, Courn D, Wilken G, et al. Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an E. coli model of septic shock; correlation with preserved circulating catecholamines. Crit Care Med. 2003;31:237–45.
5. Salvenmini D, Cuzzocreo S. Oxidative stress in septic shock and disseminated intravascular coagulation. Free Radic Biol Med. 2002;33(9):1173–85.
6. Szabó C, Módis K. Pathophysiological roles of peroxynitrite in circulatory shock. Shock. 2010;34:4–14.
7. Cuzzocreo S. Shock, inflammation and PARP. Pharmacol Res. 2005;52(1):72–82.
8. King PA, Anderson VE, Edwards JO, et al. A stable solid that generates hydroxyl radical dissociations in aqueous solutions: reaction with proteins and nucleic acid. J Am Chem Soc. 1992;114:5430–2.
9. Lange M, Hamahata A, Enkhibaatar P, et al. Assessment of vascular permeability in an ovine model of acute lung injury and pneumonia-induced Pseudomonas aeruginosa sepsis. Crit Care Med. 2008;36:1284–9.
10. Epstein FH, Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345(8):588–95.
11. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock. 2000;13:413–24.
12. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994;28(1):34–9.
13. Tsapenko M, Herasevich V, Mour G, et al. Severe sepsis and septic shock in patients with pre-existing non-cardiac pulmonary hypertensions: con temporary management and outcomes. Crit Care Resusc. 2013;15(2):103–9.
14. Suzuki S, Togari H, Yamaguchi N, et al. Nitric oxide inhibition and nitric oxide synthase inhibitor supplement for endotoxin-induced hypotension. Pediatr Int. 2001;43(4):343–9.
15. Hinder F, Stubbie H, Van Aken H, et al. Role of nitric oxide in sepsis-associated pulmonary edema. Am J Respir Crit Care Med. 1999;159(1):252–7.
16. Enkhibaatar P, Wang J, Saunders F, et al. Mechanistic aspects of inducible nitric oxide synthase-induced lung injury in burn trauma. Burns. 2011;37(4):638–45.
17. Cereda MF, Sparacino ME, Frank AR, et al. Efficacy of tracheal gas insufflation in spontaneously breathing sheep with lung injury. Am J Respir Crit Care Med. 1999;159:845–50.
18. Pearce MLEE, Yamashita J, Beazell J. Measurement of pulmonary edema. Circ Res. 1965;16:482–8.
19. Cox RA, Burke AS, Soejima K, et al. Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol. 2003;10(2):295–302.
20. Lange M, Nakano Y, Traber DL, et al. Role of different nitric oxide synthase isoforms in a murine model of acute lung injury and sepsis. Biochem Biophys Res Commun. 2010;396:286–91.
21. López A, Loiente JA, Steinrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21–30.
22. Rehberg S, Maybauer MO, Maybauer DM, et al. The role of nitric oxide and reactive nitrogen species in experimental ARDS. Front Biosci Sch Ed. 2010;12:18–29.
23. Enkhibaatar P, Joncam C, Traber L, et al. Novel ovine model of meticillin-resistant Staphylococcus aureus induced pneumonia and sepsis. Shock. 2007. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land ingpage&an=0024382-9000000000-998818. Accessed 13 Feb 2012.
24. Schuller D, Mitchell JR, Calandrino FS. Fluid balance during pulmonary edema: is fluid gain a marker or a cause of poor outcome? Chest. 1991;100:1068–75.
25. Rossaint R, Gerlach H, Schmidt-Ruhnke H, Pappert D, Lewandowski K, Steudel W, Falke K. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995;107(4):1107–15.